Register HomeChinese Version Lychee Group Register




Wilson Sonsini Goodrich & Rosati

Wilson Sonsini Goodrich & Rosati is the premier legal advisor to technology, life sciences, and other growth enterprises worldwide. We represent companies at every stage of development, from entrepreneurial start-ups to multibillion-dollar global corporations, as well as the venture firms, private equity firms, and investment banks that finance and advise them. The firm’s broad range of services and practice areas are focused on addressing the principal challenges faced by the management, boards of directors, shareholders, and in-house counsel of our clients.
The firm is nationally recognized for providing high-quality services to address the legal solutions required by its enterprise and financial institution clients. Our services include corporate law and governance, public and private offerings of equity and debt securities, mergers and acquisitions, securities class action litigation, intellectual property litigation, antitrust counseling and litigation, joint ventures and strategic alliances, technology licensing and other intellectual property transactions, tax, and employee benefits and employment law, among other areas. Our distinguished international roster of clients span a wide variety of industries, including information technology, life sciences, energy and clean technology, media and entertainment, communications, retail, and financial services.
For more information, visit



Suzhou BioBAY

Suzhou BioBAY is the key driver of life science innovation for Suzhou Industrial Park (SIP). Nearly 500 high-tech innovative companies covering drug discovery, medical device (including IVD), biotech, CRO, and nanotech have been located in BioBAY. 8000 scientists and professionals have come to join this dynamic innovative community, including 60 talents of The Recruitment Program of Global Experts.
BioBAY is playing an active role in building an interactive and collaborative innovation ecosystem:

  • Cold Spring Harbor Asia Conference Centre — cutting-edge academic resources and global technical communication
  • BioTOP — one-stop professional solutions for biomedical companies, including analysis & test, GMP verification, biomaterials trading, training, etc.
  • BioBAY Sangtian Island — commercialization base for high-tech drug, medical device and IVD companies
  • BioBAY Changshu — top class industrial base for biomedical industry with international advanced standards




Medtronic plc ( has its principal executive offices in Ireland and continues to be operationally headquartered in Minneapolis. The company is the global leader in medical technology - alleviating pain, restoring health, and extending life for millions of people around the world. Medtronic has a comprehensive product portfolio, a diversified growth profile and broad geographic reach, with more than 85000 employees in more than 160 countries, reaching $27.7billion of revenue in FY14. Currently its products and therapies involve multiple business units including cardiac rhythm disease management, coronary, cardiac surgery, endovascular, diabetes, neuromodulation / pain management, spinal and orthopedic, ENT / neurosurgery / navigation, cardiothoracic surgery, urological / urogynecological / gastroenterological, diagnostic solutions, etc. Every one second, somewhere in the world, two lives are saved or improved by a Medtronic product or therapy.



Ascentage Pharma

Ascentage is dedicated to the R&D of innovative drugs with focus on targeted anti-cancer small molecule drugs. Ascentage R&D team has proven track record in pre-clinical development, IND filing with both FDA and CFDA and clinical development. Ascentage has its own cGMP production facility and is capable of conducting small molecule drug R&D according to international standards. Ascentage is one of the leading innovative drug R&D companies in China with ten small molecule drugs in pipeline and four class 1.1 INDs approved by CFDA, as well as two INDs approved by FDA and in Australia. Ascentage is the only company with three novel small molecules targeting different Bcl-2 family proteins with potential to be the best-in-class for Bcl-2 proteins driven malignancies. Our IAP inhibitor APG-1387 is in phase I trials in Australia and in China. Ascentage team developed the best-in-class compounds against MDM2-p53 target which entered into a global R&D collaboration with Sanofi Aventis for total US$398 million in 2010. Ascentage received strategic seed funding of US$3millions from 3SBio Inc. in 2010, and received Series A funding of US$16.5 million from leading venture capital investors in 2015.


BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 300 scientists, clinicians and staff in mainland China, the United States, Australia and Taiwan, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for cancer. BeiGene is working to create combination solutions aimed to have both a meaningful and lasting impact on cancer patients.

CANbridge Life Sciences

CANbridge Life Sciences, Ltd. is a clinical-stage bio-pharmaceutical company accelerating development and commercialization of specialty oncology products for treating and diagnosing cancers that prevalent or unique among Chinese and Asians. CANbridge leverages multiple partnerships with Western bio-pharmaceutical companies with clinical-stage pharmaceutical, medical device or diagnostic products that are either unavailable in China/North Asia or address medical needs that are underserved in the region. It has two lead candidates under development in glioblastoma and squamous esophageal cancer. Led and backed by a highly-seasoned executive team, with extensive Chinese drug development experience, CANbridge has the capability to select, acquire, develop and commercialize future therapeutics and diagnostics targeting the unmet medical needs of Chinese and East Asian patients with serious or critical conditions. CANbridge is privately-held and headquartered in Beijing, China. For more information, please go to

Eight Roads Ventures

Eight Roads Ventures China (ERVC), formerly known as Fidelity Growth Partners Asia, is the proprietary venture capital arm of FIL, Fidelity International Limited. As a private venture capital investor, ERVC dedicates its long-term patient investment approach in ventures specialized in Healthcare and Biosciences , FinTech, Consumer Technology and Enterprise Technology, backing and building innovative and ambitious early-stage businesses looking to disrupt or lead their chosen markets. By combining a collaborative approach Through FIL’s global network and an over 20-year history of venture investing, ERVC provides substantial global investing scale, expertise and market reach in China. A strong track record includes investments in market leaders such as Alibaba, China PnR, Wuxi PharmaTech, Hile, Innovent, Adagene and Hua Medicine.


EY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.


Founded in August 2011, Innovent aims to produce quality complex biopharmaceutical products that will be affordable to people in China and around the world. With its focus on innovation and global cGMP standards, Innovent stands out in China’s biopharmaceutical industry and has attracted investments from world-class financial firms such as Fidelity, Lilly Asia Ventures, Legend Capital, SDIC Fund Management, China Life, Temasek, Hillhouse, Ping An, Taikang Insurance Group, and others. In 2015, Innovent entered a strategic alliance with Eli Lilly & Company to co-develop and co-commercialize multiple innovative biologics in China, while outside of China Lilly develops and commercializes multiple immuno-oncology biologics within the alliance. The transaction not only brought the largest upfront payment from a global company to a Chinese company, but also was first time a biologic was out-licensed to a global company for global development.
Innovent has been recognized by outside organizations for its significant contributions in innovation. In January 2017, Innovent CEO Michael Yu was selected by CCTV as the Person of the Year in Innovation. In June 2016, Innovent was invited to attend the National “12th Five-Year” Science and Technology Innovation Achievement Exhibition, where Innovent was widely recognized by national leaders. In 2015, Innovent was invited to be the representative on the delegation for ‘The 6th U.S. – Sino Innovation Dialogues’ in Washington DC, and Innovent’s R&D progress was voted as one of the “Top Ten Breakthroughs in the China Biopharmaceutical Industry”


Established in 1989, OrbiMed is the world’s largest healthcare and life sciences-dedicated investment firm. OrbiMed manages approximately USD$13 billion assets and has invested in over 450 companies across a wide range of therapeutic categories and stages of development. OrbiMed Asia manages three Asia-focused PE/VC funds, totaling over $1 billion. It has made investments in 36 companies. OrbiMed’s public equity funds have invested approximately USD$2 billion in Asia public companies. For More information, please vist www orbimed com.

SDIC Fund Management Company

SDIC Fund Management Company Ltd.("SDIC Fund Management" hereinafter), partially owned by SDIC Group, is an independent private equity fund manager established in Aug.2009. We currently advise and manage over RMB 50 billion of capital. The limited partners include a wide range of institutional investors across China. SDIC Fund Management is one of the largest professional private equity funds in China. The core strategy of SDIC Fund Management is to invest in market leading companies with attractive growth prospects and outstanding management teams. In partnership with the portfolio companies and their management teams, we aim to contribute strategically and add business value to the companies. SDIC Fund Management prides itself on its ability to forge effective and mutually rewarding partnerships with exceptional management teams to execute its strategy of investing in quality businesses, and adding value to make them grow to become leaders in their respective industry. SDIC Fund Management's primary focus in China includes advanced manufacturing, health care, TMT and environmental protection.

Tigermed Consulting

Hangzhou Tigermed Consulting Co., Ltd(stock symbol: 300347) is a leading Contract Research Organization (CRO) in China dedicated to provide professional full clinical trial services. Since inception in 2004, Tigermed has been committed to accelerating medical product development with costs efficiency and quality. Headquartered in Hangzhou, Tigermed operates 33 subsidiaries, 60 offices across China and 10 overseas offices in Hong Kong, Taiwan, USA, Canada, Korea, Australia, Japan, Malaysia, Singapore and India with over 2500 full time staffs. Tigermed has set up international standard SOPs and serviced more than 600 local and global clients in the conduct of over 600 clinical trials. Tigermed is recognized as “The Innovative CRO” in China,owning to our involvement of 80 innovative drugs. For more information about Tigermed, please visit

Wuxi Ventures

WuXi Healthcare Ventures is a leading cross-border venture capital firm focused in the life sciences and healthcare, with offices in Shanghai and Boston. The firm has assembled a team of seasoned investors and company builders with deep roots in science, technology, and innovation. The firm’s mission is to find, seed, and develop life science and healthcare businesses that can benefit the most from the firm’s operational expertise, strategic support, capital, and the patience of a long-term perspective. For more information, please visit

Xynomic Pharmaceuticals

Xynomic is a US company focusing on in-licensing, developing and commercializing innovative oncology drugs worldwide. The company owns an impressive pipeline, including Abexinostat (worldwide rights) and Avasimibe (Greater China rights). Abexinostat is a potentially best-in-class innovative HDAC inhibitor targetinghematological and solid tumors. 14 Phase 1 and 2 clinical trials of Abexinostat in US, EU and Asia have already been completed, demonstrating itis clinically active in multiple tumor settings with a more favorable safety profile among HDAC products. Xynomic will initiate Phase 3 registrational trials worldwide in Q3’2017. Avasimibe is a first-in-class drug with novel MOA targeting prostate and pancreatic cancers. The company’s founding executives worked at leading multinational companies (Schering, Eli Lilly, Merck and Roche) in R&D roles. Mr. Y. Mark Xu, Co-founder, Chairman, CEO and President, is a successful serial entrepreneur and had in the past co-founded 2 US-China biopharmaceutical companies, generating RMB 2.5 billion for shareholders.



Bayhelix Group

BayHelix Group is a non-profit, invitation-only organization of business leaders of Chinese heritage that fosters the growth of the life sciences and healthcare industry around the Pacific Rim and beyond. Founded in 2001, BayHelix has grown to over 300 members throughout the U.S., Canada, and Greater China. The membership base covers virtually all of the world’s top pharmaceutical and biopharmaceutical companies, as well as leading services and investment firms. Over one third of the members are senior executives, over 80% have PhDs in the life sciences, and nearly half have MBAs from the leading business schools in U.S.


Founded by industry-recognized editors, RNDer and PharmaDJ are the leading publications providing value-added analysis for pharmaceutical and biotechnology companies doing business in China. With a mission to facilitate drug R&D and regulatory science in China, we talk to regulators and key opinion leaders from industry to piece together the China market puzzle for our readers.



ChinaBio Group

Since its founding in 2007, ChinaBio® Group has created a broad platform of capabilities connecting China life science with the world. ChinaBio has helped western life science companies identify over 400 licensing and acquisition opportunities and raise over USD 500 million in funding in China.

  • Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 5,000 attendees.
  • Consulting: ChinaBio helps global life science companies to define and execute a successful strategy in China.
  • Capital: ChinaBio launched its first VC fund in 2014 focused on bringing Western companies and technologies to China.
  • Publishing: ChinaBio® Today is the most widely read online and email newsletter on China's life science industry, with over 18,000 readers.

Supporting Media Partner:


BioCentury: Biopharma's Knowledge Center

BioCentury is the essential source of intelligence for a global audience of biotech and pharmaceutical company professionals, investors, researchers, service providers and industry stakeholders who demand deep industry knowledge, data-driven analysis, independent perspective and a commitment to accuracy. Our insight, trusted reporting and in-depth analysis are built on independent, objective surveillance of the biotechnology sector, producing the industry's most respected journals and data solution resources, since 1993. For more information please



BioCentury China Healthcare Summit

The 2017 BioCentury China Healthcare Summit is an annual forum to identify the essential next steps to creating a modern healthcare ecosystem in China based on a foundation of scientific, business and policy innovations. This VIP event is organized by BioCentury and BayHelix in collaboration with McKinsey & Co. It is a closed-door meeting limited to senior-level biopharma and medtech executives, investors and academia. The Summit features two days of action-oriented discussion and networking among peers. Attendees will receive an exclusive conference report from McKinsey documenting market trends and identifying business imperatives for China healthcare innovators. For more information, please contact Joshua Berlin at or WeChat ID: "joshberlin", or visit our website:


Founded in 2002, GBI ( is an information, applications and services company focused on the healthcare industry. It boasts a diverse portfolio of marketing intelligence solutions that enable organizations and individuals to make data-driven decisions and communicate more effectively. Over 15 years of development, GBI has built a global presence with around 200 staff across four locations in Shanghai, Beijing, São Paolo, and Washington, DC. Our first database product was launched in 2009, and we have now built a portfolio based around the flagship brands of SOURCE, DEVINT, METRIX and NAVIS, covering the markets of China, Latin America, and the United States. GBI is now a trusted provider for the pharmaceutical and medtech industries, with established long-term partnerships with multinational industry players.


Lingmed helps pharmaceutical/device industry to improve productivities, make better decisions with intelligence databases. Currently Lingmed is the exclusive partner of EvaluatePharma and Biotechgate in China and GBI Source China’s local market partner. Lingmed databases cover more than 36,000 pharma, medtech and biotech companies, over 45,000 innovative products’ active licensing opportunities. Lingmed databases are the trusted source for life science market intelligence and analysis with exclusive consensus forecasts, which supports life science and healthcare companies in their strategic decision-making. Lingmed also supports oversea innovative assets to enter China market on deal making with local BD professionals.

Copyright © 2017 Consortium of China Healthcare. All rights reserved. Join Our Mailing List